Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 25, 2025 13:10 ET | Source: Starton Therapeutics Inc. PARAMUS, N.J.,…
